<DOC>
	<DOCNO>NCT00946985</DOCNO>
	<brief_summary>The study ass use paliperidone palmitate compare oral risperidone delaying time relapse patient recently diagnose schizophrenia high risk relapse .</brief_summary>
	<brief_title>28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone Treating Adults Diagnosed With Schizophrenia Within Past 5 Years</brief_title>
	<detailed_description>This Prospective , Randomized , Active-controlled , Rater-blinded Study ass efficacy paliperidone palmitate compare oral risperidone delaying time relapse patient recently diagnose schizophrenia high risk relapse . Recently diagnose define first diagnosis psychotic disorder within 5 year prior screen . High risk relapse define documented occurrence 3 period breakthrough symptom require change patient care per investigator 's judgment ( e.g. , increase dose , addition new drug , increase level psychiatric care , notable increase frequency intensity patient contact require maintain outpatient status , psychiatric hospitalization , etc . ) within previous 24 month , include 1 period within previous 6 month . Safety evaluation include Adverse Event ( AE ) reporting , hematology clinical chemistry laboratory test , vital sign , electrocardiogram ( ECG ) , evaluation suicidality sexual functioning . Patients receive either paliperidone palmitate 50 , 75 , 100 , 150 mg eq . monthly injection two year oral risperidone 2 , 4 , 6 , 8 mg tab daily two year .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients must , opinion investigator , able understand inform consent form approve Institutional Review Board ( IRB ) Independent Ethics Committee ( IEC ) , appropriate All patient must sign study informed consent document indicate understand purpose procedure require study willing participate study Must current diagnosis schizophrenia must 3 period breakthrough symptom require change patient care determine investigator ( e.g . increase dose , addition new drug , hospitalization , increase level psychiatric care , notable increase frequency intensity patient contact require maintain outpatient status , etc . ) within previous 24 month , include 1 period within previous 6 month Women must postmenopausal , surgically sterile , otherwise incapable pregnancy , abstinent , sexually active , practice highly effective method birth control entry , must agree continue use method contraception throughout study Women childbearing potential must negative urine pregnancy test screening Patients must cooperative reliable , agree receive regular injection , willing/able adhere prohibition restriction specify protocol . Patients unable provide consent involuntarily commit psychiatric hospitalization Have attempt suicide within 12 month screen imminent risk suicide violent behavior Have positive urine drug screen test barbiturate , cocaine , amphetamine , opiate screen Patients first episode psychosis Patients currently meet criterion Axis I diagnosis except substance abuse Axis II diagnosis Mental Retardation Borderline Personality Disorder Meet Diagnostic Statistical Manual Mental Health Disorders fourth edition ( DSMIV ) definition substance dependence ( except nicotine caffeine dependence ) within 6months prior entry Patients know allergy , hypersensitivity ( anaphylaxistype reaction ) , intolerance paliperidone palmitate , risperidone , Risperdal速 , Risperdal速 Consta速 , INVEGA速 excipients Patients receive Long Acting Therapy ( LAT ) treatment within 2 injection cycle prior screen Women pregnant breastfeeding , plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal</keyword>
	<keyword>Paliperidone Palmitate</keyword>
	<keyword>Invega Sustenna</keyword>
</DOC>